B.R. Baker

Factors in the Design of Active-Site-Directed Irreversible Inhibitors

Analogs of tetrahydrofolic acid. XII. On the relative contribution by the 2-amino and 4-hydroxy groups of 2-amino-5-(3-anilinopropyl)-6-methyl-4-pyrimidinol to inhibition of folic reductase and thymidylate synthetase †‡

Analogs of Tetrahydrofolic Acid XXIV: Further Observations on the Mode of Pyrimidyl Binding to Dihydrofolic Reductase and Thymidylate Synthetase by the 2-amino-5-(3-anilinopropyl)-6-methyl-4-pyrimidinol Type of Inhibitor

Analogs of Tetrahydrofolic Acid XXVII: Hydrophobic Bonding to Dihydrofolic Reductase by 2-Amino-4,6-disubstituted-5-alkylpyrimidines and 1-Alkyl-4,6-diamino-1,2-dihydro-s-triazines

Analogs of tetrahydrofolic acid XXVIII. Mode of pyrimidine binding to dihydrofolic reductase ph profile studies

Nonclassical antimetabolites XVIII. Simulation of 5′-phosphoribosyl binding II. ω-uracil alkanoic acids related to 2′-deoxyuridylate

Analogs of tetrahydrofolic acid. XXIX. Hydrophobic bonding to dihydrofolic reductase. II. On the mode of phenyl binding of 1‐aryl‐4,6‐diamino‐1,2‐dihydro‐2,2‐dimethyl‐s‐triazines

Analogs of tetrahydrofolic acid. XXI. Synthesis of 6‐bromomethyl‐5‐(p‐chlorophenyl)‐2,4‐diaminopyrimidine and its evaluation as a dihydrofolic reductase inhibitor

Differential Inhibition of Dihydrofolic Reductase from Different Species

Analogs of tetrahydrofolic acid. XIII. On the mode of binding of the anilino group of 2-amino-5-(3-anilinopropyl)-6-methyl-4-pyrimidinol to dihydrofolic reductase and thymidylate synthetase †‡